InterStim® Amplitude Study

Overview

This feasibility study will explore the effects of three different InterStim amplitude settings on overactive bladder symptoms (OAB).

Full Title of Study: “InterStim® Amplitude Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: Single (Participant)
  • Study Primary Completion Date: November 6, 2019

Detailed Description

This is a prospective, randomized, multicenter, single-blinded study to explore the efficacy and quality of life (QoL) of 3 different amplitude settings.

Interventions

  • Device: InterStim Therapy
    • Device Programming

Arms, Groups and Cohorts

  • Experimental: Amplitude Setting #1
    • InterStim Therapy will be set to amplitude parameter #1.
  • Experimental: Amplitude Setting #2
    • InterStim Therapy will be set to amplitude parameter #2.
  • Experimental: Amplitude Setting #3
    • InterStim Therapy will be set to amplitude parameter #3.

Clinical Trial Outcome Measures

Primary Measures

  • Change in Urinary Urge Incontinence (UUI) Episodes Per Day From Baseline to 12 Weeks.
    • Time Frame: 12 weeks
    • Symptoms related to OAB were evaluated using paper voiding diaries. Subjects were trained to complete the urinary voiding diaries for 3-days.

Secondary Measures

  • Change in QoL Using ICIQ-OAB QOL From Baseline to 12 Weeks.
    • Time Frame: 12 weeks
    • International Consultation on Incontinence Modular Questionnaire – Overactive Bladder Symptoms Quality of Life Questionnaire The questionnaire consists of 4 subscales and a single item on urinary symptom interference. The four subscales of Concern (7 items), Coping (8 items), Sleep (5 items), and Social (5 items) are measured on a scale from 0-100 using a range percentile transformation on the summed value from individual listed items. The Health-Related Quality of Life (HRQL) score is a calculated score with a range from 0 to 100 using a range percentile transformation on the summed value from the subscales. Subjects were asked a urinary symptom interference question. “Interference” was measured on a scale from 0-10. A positive change in Concern, Coping, Sleep, Social, and HRQL indicates improvement in Quality of Life; a negative change in Interference indicates improvement in Quality of Life.

Participating in This Clinical Trial

Inclusion Criteria

1. Primary diagnosis of urinary urge incontinence (UUI) as demonstrated on a 3-day baseline voiding diary demonstrating at least 3 UUI episodes 2. Female subjects 18 years of age or older 3. Candidate for InterStim Lead Placement 4. Willing and able to accurately complete voiding diaries, questionnaires, attend visits, and comply with the study protocol (which includes maintenance of InterStim II programming settings over the course of the study) 5. Willing and able to provide signed and dated informed consent 6. Willing to maintain current regimen (dosage and frequency) of any overactive bladder (OAB) medication Exclusion Criteria:

1. Have neurological conditions such as multiple sclerosis, clinically significant peripheral neuropathy or spinal cord injury 2. History of diabetes unless the diabetes is well-controlled through diet and/or medications 3. Symptomatic urinary tract infection (UTI) 4. Have primary stress incontinence or mixed incontinence where the stress component overrides the urge component 5. Treatment of urinary symptoms with botulinum toxin in the past 9 months or any plan to have botulinum toxin treatment during the study 6. Implanted with a neurostimulator, pacemaker, or defibrillator 7. Have knowledge of planned MRIs, diathermy, microwave exposure, high output ultrasonic exposure, or radio frequency (RF) energy exposure not included within the scanning conditions provided with the MRI Guidelines for InterStim Therapy 8. Women who are pregnant or planning to become pregnant 9. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements. 10. Currently enrolled or planning to enroll in a potentially confounding clinical study during the course of the study (co-enrollment in concurrent studies is only allowed when documented pre-approval is obtained from the Medtronic study manager (or designee).

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • MedtronicNeuro
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.